LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Oncology Focus Apmonia Therapeutics is committed to developing personalized anti-cancer immunotherapies targeting tumors overexpressing thrombospondin-1, which presents opportunities to collaborate with biotech firms and hospitals focusing on advanced cancer treatments.

Recent Funding Growth The company secured over 14.5 million USD through recent venture funding and grants, indicating strong investor confidence and potential for scaling R&D collaborations and clinical trial activities.

Strategic Partnerships With a recent licensing agreement with SATT Nord and collaborations with public sector investors like Bpifrance, Apmonia is positioned to expand its innovative peptide portfolio, creating potential sales channels for licensing and joint development deals.

Focus on Precision Medicine Development of companion diagnostic kits to monitor TSP-1 levels offers opportunities to partner with diagnostic and personalized medicine providers targeting tailored cancer therapies.

Market Entry Potential Despite current revenue levels, Apmonia’s innovative approach and recent funding suggest it is in early stages of commercialization, providing prospects to introduce therapeutic and diagnostic products to biotech and pharma companies expanding in oncology.

Apmonia Therapeutics Tech Stack

Apmonia Therapeutics uses 8 technology products and services including MySQL, Google Fonts API, jQuery, and more. Explore Apmonia Therapeutics's tech stack below.

  • MySQL
    Database
  • Google Fonts API
    Font Scripts
  • jQuery
    Javascript Libraries
  • imagesLoaded
    Javascript Libraries
  • jQuery Migrate
    Javascript Libraries
  • Twenty Seventeen
    Web Platform Extensions
  • Essential Addons for Elementor
    Web Platform Extensions
  • jQuery.scrollTo
    Web Tools And Plugins

Apmonia Therapeutics's Email Address Formats

Apmonia Therapeutics uses at least 1 format(s):
Apmonia Therapeutics Email FormatsExamplePercentage
F.Last@apmonia-therapeutics.comJ.Doe@apmonia-therapeutics.com
43%
L.First@apmonia-therapeutics.comD.John@apmonia-therapeutics.com
7%
F.Last@apmonia-therapeutics.comJ.Doe@apmonia-therapeutics.com
43%
L.First@apmonia-therapeutics.comD.John@apmonia-therapeutics.com
7%

Frequently Asked Questions

Where is Apmonia Therapeutics's headquarters located?

Minus sign iconPlus sign iconApmonia Therapeutics's main headquarters is located at 2 Esplanade Roland Garros Reims, Grand Est 51100 France. The company has employees across 1 continents, including Europe.

What is Apmonia Therapeutics's official website and social media links?

Minus sign iconPlus sign iconApmonia Therapeutics's official website is apmonia-therapeutics.com and has social profiles on LinkedInCrunchbase.

What is Apmonia Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign iconApmonia Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Apmonia Therapeutics have currently?

Minus sign iconPlus sign iconAs of March 2026, Apmonia Therapeutics has approximately 19 employees across 1 continents, including Europe. Key team members include Chief Executive Officer: A. J.Chief Regulatory Officer: L. L.Chief Operating Officer: S. G.. Explore Apmonia Therapeutics's employee directory with LeadIQ.

What industry does Apmonia Therapeutics belong to?

Minus sign iconPlus sign iconApmonia Therapeutics operates in the Biotechnology Research industry.

What technology does Apmonia Therapeutics use?

Minus sign iconPlus sign iconApmonia Therapeutics's tech stack includes MySQLGoogle Fonts APIjQueryimagesLoadedjQuery MigrateTwenty SeventeenEssential Addons for ElementorjQuery.scrollTo.

What is Apmonia Therapeutics's email format?

Minus sign iconPlus sign iconApmonia Therapeutics's email format typically follows the pattern of F.Last@apmonia-therapeutics.com. Find more Apmonia Therapeutics email formats with LeadIQ.

How much funding has Apmonia Therapeutics raised to date?

Minus sign iconPlus sign icon As of March 2026, Apmonia Therapeutics has raised $7.6M in funding. The last funding round occurred on Jul 15, 2024 for $7.6M.

When was Apmonia Therapeutics founded?

Minus sign iconPlus sign iconApmonia Therapeutics was founded in 2019.

Apmonia Therapeutics

Biotechnology ResearchGrand Est, France11-50 Employees

Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Our innovative technological approach is to target tumors overexpressing matricellular protein thrombospondin-1 (TSP-1).

Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1.

Section iconCompany Overview

Headquarters
2 Esplanade Roland Garros Reims, Grand Est 51100 France
Website
apmonia-therapeutics.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $7.6M

    Apmonia Therapeutics has raised a total of $7.6M of funding over 4 rounds. Their latest funding round was raised on Jul 15, 2024 in the amount of $7.6M.

  • $1M

    Apmonia Therapeutics's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $7.6M

    Apmonia Therapeutics has raised a total of $7.6M of funding over 4 rounds. Their latest funding round was raised on Jul 15, 2024 in the amount of $7.6M.

  • $1M

    Apmonia Therapeutics's revenue is estimated to be in the range of $1M

Company Leadership

  • Stylized image of a person
    A. J.
    Chief Executive Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    L. L.
    Chief Regulatory Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. G.
    Chief Operating Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. L.
    Co-Founder And Board Member
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. D.
    Co-Founder & Chair Of The Scientific And Clinical Advisory Board
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    A. M.
    Senior Non-Clinical Project Manager
    Phone icon
    Mobile Phone
  • Stylized image of a person
    M. G.
    Computational Engineer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. F.
    Directeur Financiers À Temps Partagé
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. R.
    Team Discovery
    Phone icon
    Mobile Phone
  • Stylized image of a person
    M. E.
    Engineer R&d Department
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.